Browse Category:

Categories

[Search within category]

New Effective Low-Cost Vaccines

Enteric disease and respiratory diseases are major problems worldwide which greatly impact human health, as well as animal health. Current vaccine approaches are limited by numerous factors, including production costs, efficacy, safety, requirement of adjuvants, and storage conditions. 

Pyrite Shrink-Wrap Laminate As A Hydroxyl Radical Generator

The invention is a diagnostic technology, as well as a research and development tool. It is a simple, easy to operate, and effective platform for the analysis of pharmaceuticals and biological species. Specifically, this platform generates hydroxyl radicals for oxidative footprinting – a technique commonly employed in protein mapping and analysis. The platform itself is inexpenisve to fabricate, scalable, and requires nothing more than an ordinary pipet to use. In addition, it is highly amenable to scale-up, multiplexing, and automation, and so it holds promise as a high-throughput method for mapping protein structure in support of product development, validation, and regulatory approval in the protein-based therapeutics industry.

Salmonella-Based Gene Delivery Vectors and their Preparation

Nucleic acid-based gene interference technologies, including ribozymes and small interfering RNAs (siRNAs), represent promising gene-targeting strategies for specific inhibition of mRNA sequences of choice. A fundamental challenge to use nucleic acid-based gene interfering approaches for gene therapy is to deliver the gene interfering agents to appropriate cells in a way that is tissue/cell specific, efficient and safe. Many of the currently used vectors are based on attenuated or modified viruses, or synthetic vectors in which complexes of DNA, proteins, and/or lipids are formed in particles, and tissue-specific vectors have been only partially obtained by using carriers that specifically target certain cell types. As such, efficient and targeted delivery of M1GS sequences to specific cell types and tissues in vivo is central to developing this technology for gene targeting applications. Invasive bacteria, such as Salmonella, possess the ability to enter and transfer genetic material to human cells, leading to the efficient expression of transferred genes. Attenuated Salmonella strains have earlier been shown to function as a carrier system for delivery of nucleic acid-based vaccines and anti-tumor transgenes. Salmonella-based vectors are low cost and easy to prepare. Furthermore, they can be administrated orally in vivo, a non-invasive delivery route with significant advantage. Thus, Salmonella may represent a promising gene delivery agent for gene therapy. Scientists at UC Berkeley have developed a novel attenuated strain of Salmonella, SL101, which exhibited high gene transfer activity and low cytotoxicity/pathogenicity while efficiently delivering ribozymes, for expression in animals. Using MCMV infection of mice as the model, they demonstrated that oral inoculation of SL101 in animals efficiently delivered RNase P-based ribozyme sequence into specific organs, leading to substantial expression of ribozyme and effective inhibition of viral infection and pathogenesis. This strategy could easily be adopted deliver other gene targeting technologies.

Monoclonal Antibody Against Cer164 (Clone 11)

Mouse monoclonal antibody against the human centrosomal protein 164kDa (Cep164). This antibody binds to the phosphorylation site of Cep164 and has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibody Against ATR-IP (Clone 5)

Mouse monoclonal antibody against the human ATR-interacting protein (ATR-IP). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibody Against Cer164 (Clone 26)

Mouse monoclonal antibody against the human centrosomal protein 164kDa (Cep164). This antibody binds to the phosphorylation site of Cep164 and has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibody Against PNPase (Clone 4C11)

Mouse monoclonal antibody against the human mitochondrial polyribonucleotide nucleotidyltransferase 1 (PNPase). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibody Against Pnpase (Clone 2A2)

Mouse monoclonal antibody against the human mitochondrial polyribonucleotide nucleotidyltransferase 1 (PNPase). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibodies Against Spc24/25 (Clone 2A10)

Mouse hybridoma cell line secret antibody against the human Kinetochore protein Spc24 (SPC24) and Kinetochore protein Spc25 (SPC25). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibodies Against Spc24/25 (Clone 2C8)

Mouse hybridoma cell line secret antibody against the human Kinetochore protein Spc24 (SPC24) and Kinetochore protein Spc25 (SPC25). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Novel In Vitro Method for Generating Human Dendritic Cells for Immunotherapy

Researchers in the UCLA Department of Pathology and Laboratory Medicine have developed a new method for generating and expanding human CLEC9A+ dendritic cells that can be used for a wide variety of immunotherapy applications.

Monoclonal Antibody against ATR-IP (Clone 11)

Mouse monoclonal antibody against the human ATR-interacting protein (ATR-IP). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibody Against CEP164 (Clone 13)

Mouse monoclonal antibody against the human centrosomal protein 164kDa (Cep164). This antibody binds to the phosphorylation site of Cep164 and has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Monoclonal Antibody Against CEP164 (Clone 17)

Mouse monoclonal antibody against the human centrosomal protein 164kDa (Cep164). This antibody binds to the phosphorylation site of Cep164 and has been tested for use in immunoprecipitation and western blot.

Monoclonal Antibodies Against Chk2 (Clone 4B8)

Mouse monoclonal antibody (clone 4B8) against the human Serine/threonine-protein kinase Chk2. This antibody has been tested for use in immunoprecipitation and western blot.

Monoclonal Antibodies Against Mtpap (Clone 1D3)

Mouse monoclonal antibody against the human Poly (A) RNA polymerase, mitochondrial (mtPAP). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Cyclic Amp-Elevating Drugs As Adjuvants - 2014-084

Effective adjuvants enhance antigen immunogenicity and/or modulate the type of immunity (e.g., humoral vs. cellular immune response), and, in theory, an optimal antigen-adjuvant combination should activate the both arms of the immune system (innate and adaptive immunity). Different adjuvants work via different mechanisms and, ultimately, the best adjuvant for any specific vaccine will be chosen on the basis of compatibility with the delivery route (e.g., systemic vs. mucosal), ability to provoke the desired immune response (e.g., humoral vs. cellular immunity), and relevance to a particular stage of the required anti-microbial protection (e.g., preventive vs. therapeutic immunity). One way to achieve these diverse goals is to use a combination of complementary, synergistic adjuvants and this is one current practice. However, an adjuvant that could trigger the immunomodulatory cascade upstream of current options could simplify the design of safe and effective vaccines and revolutionize modern day vaccinations.

NOVEL GLIOMA-SPECIFIC VACCINE FOR PEDIATRIC AND YOUNG-ADULT PATIENTS

UCSF researchers have developed a vaccine against pediatric gliomas by targeting a novel epitope.  

Monoclonal Antibody Against mtPAP (Clone 3D2)

Mouse monoclonal antibody against the human Poly (A) RNA polymerase, mitochondrial (mtPAP). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot. .

Monoclonal Antibody Against PNPase (Clone 3H5)

Mouse monoclonal antibody against the human mitochondrial polyribonucleotide nucleotidyltransferase 1 (PNPase). This antibody has been tested for use in immunocytochemistry/immunofluorescence, immunoprecipitation, and western blot.

Erodible Polymer Particle Oral Vaccine Adjuvant

Brief description not available

Modulation of in utero Immune Programming

The in utero environment is an important determinant of potential disease. In particular, epidemiological evidence links dysmetabolic conditions during pregnancy with atherosclerosis, diabetes and hypertension later in life, which then leads to a wave of cardiovascular disease in the offspring. It has further been demonstrated that maternal hypercholesterolemia is one of the causes of developmental programming of atherosclerosis and is associated with increased fatty streak formation in human fetal arteries and accelerated progression of atherosclerosis during normocholesterolemic childhood.

Linear Lipopeptides As Treatments For Infectious Diseases

Leishmaniasis is a debilitating disease prevalent across many inter-tropical regions of the world. Caused by over twenty species of intracellular parasite from the genus Leishmania, leishmaniasis can present itself in a number of different clinical manifestations including cutaneous, mucosal and visceral forms of the disease. Both the cutaneous and mucosal forms can cause severe disfigurements to patients including ulcerative skin lesions and the destruction of the mucous membranes of the nose, mouth and throat leading to permanent disfigurement and frequent social ostracization. A shortfall of affordable and clinically efficacious treatments has led World Health Organization to designate leishmaniasis as a category 1 disease, signifying that it is an emerging and uncontrolled global health problem. Human African trypanosmiasis or Sleepign sickness is a parasitic disease of people and animals, caused by protozoa of the species Trypanosoma brucei and transmitted by the tsetse fly. It is estimated that 50,000 to 70,000 people are currently infected. The current standard treatment for first stage trypanosomiasis employs administering intravenous pentamidine (for T.b. gambiense) or intravenous suramin (for T.b. rhodesiense).

Immunogenic Peptides as Vaccines against Herpes Simplex Virus

Immunogenic peptides isolated from HSV seropositive asymptomatic (ASYMP) individuals induce a CD8+ T cell- dependent protective immunity against herpes virus in a mammal.

Automated Chemoenzymatic Synthesis Of Glycans And Glyconconjugates

Providers of research tools have manufactured and synthesized peptides, proteins, and DNA inexpensively for the scientific community; and yet the synthesis of carbohydrates has yet to be automated or streamlined. Researchers at the University of California, Davis have developed a novel method to automate the synthesis of glycans and glycoconjugates.

  • Go to Page:

University of California
Innovation Alliances and Services

1111 Franklin Street, 5th Floor,Oakland,CA 94607-5200 |
http://www.ucop.edu/ott/
Tel: 510.587.6000 | Fax: 510.587.6090 | UC.technologies@ucop.edu